Oncology

Female researcher in a laboratory
#Antibiotic resistance #Antibiotics #Antibody-based therapeutics #Antimicrobial resistance (AMR) #Cancer research #Carbon emissions #Environmental impact #Green lab movement #Immunotherapy #Interview #Lab technology #Molecular Biology #Oncology #Sustain #T cell activation

New podcast: Strategies and challenges in drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Strategies and challenges in therapeutic development and lab practice”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “The inner workings of antibiotics”, “Targeting advances in immunotherapies”, and… Read More

#News

#Cancer vaccine #CAR-T #Cell therapy #Immunotherapy #Oncology

New DDW Highlights podcast: 19 August 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week has seen some incredible advances in immunotherapy, including the development of a therapy… Read More

#News

T cell attacking a cancer cell
#Antibodies #Immunotherapy #Oncology #Phase I trial #Rockefeller University

Immunotherapy drug eliminates aggressive cancers

A Phase I clinical trial of CD40 agonist antibody 2141-V11 has shown positive results, with six patients seeing their tumours shrink.  CD40 is a cell surface receptor and member of the tumour necrosis factor (TNF) receptor superfamily, proteins that are largely expressed by immune cells.  … Read More

#Cancer Research #News #Trending News

Pancreatic cancer
#Autophagy #Cancer Research UK #KRAS #Oncology #Pancreatic cancer

Autophagy disruption provides clues to cancer development

Scientists have uncovered dementia-like behaviour in pancreas cells at risk of turning into cancer.   The findings provide clues that could help in the treatment and prevention of pancreatic cancer, a difficult-to-treat disease linked to 6,900 deaths in the UK every year.   The research was… Read More

#Cancer Research #News

Test for KRAS mutation
#Bayer #KRAS #Kumquat Biosciences #Oncology #Precision medicine

Bayer and Kumquat collaborate on precision oncology

Bayer and Kumquat Biosciences have entered into an exclusive global license and collaboration agreement to develop and commercialise Kumquat’s KRAS G12D inhibitor.   Under the agreement, Kumquat is responsible for the initiation and completion of the Phase Ia study, while Bayer will complete development and commercial activities.  Kumquat received US Food… Read More

#Business & Investment #Cancer Research #News

#Cancer vaccine #CAR-T #Cell therapy #Immunotherapy #Oncology

This week in drug discovery (11-15 August) 

News round-up for 11-15 August by DDW Senior Digital Content Editor Diana Turner. This week has seen some incredible advances in immunotherapy, including the development of a therapy that combines natural killer and CAR-T cells, and an off-the-shelf cancer vaccine that could revolutionise treatment for patients with one… Read More

#News

Natural killer cells
#CAR-T #Natural killer cells #Oncology #Ovarian cancer #UCLA

Scientists develop CAR-NKT cell therapy for ovarian cancer

A new type of immunotherapy called CAR-NKT cell therapy has been shown to be more effective at fighting ovarian cancer than conventional CAR-T cell therapy.   Unlike current cellular immunotherapies that require patient-specific manufacturing and can cost hundreds of thousands of dollars, CAR-NKT cells can be produced… Read More

#Cancer Research #Editor's Choice #News

Pancreatic cancer
#Cancer vaccine #Colorectal cancer #Gene mutation #Oncology #Pancreatic cancer #UCLA

Off-the-shelf cancer vaccine shows promise in KRAS-driven cancers

A novel cancer vaccine that stimulates the immune system to target one of the most common cancer-driving mutations has shown encouraging early results in patients with pancreatic and colorectal cancer.  The study was led in part by investigators at the UCLA Health Jonsson Comprehensive Cancer Center and… Read More

#Cancer Research #Editor's Choice #News

CAR-T cell therapy
#Advanced Therapies #CAR-T #Cell therapy #FDA #Galapagos #Lymphoma #Oncology

FDA RMAT designation for mantle cell lymphoma cell therapy

The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to GLPG5101, a second generation anti-CD19/4-1BB CAR-T product candidate for the treatment of relapsed/refractory mantle cell lymphoma (R/R MCL).   To qualify for RMAT designation, GLPG5101 demonstrated preliminary clinical evidence suggesting it has the potential to… Read More

#News #Regulatory

Laboratory research
#Clinical trial #Faron Pharmaceuticals #Oncology #Phase II trial

Faron reports 43% complete remission rate in MDS

Faron Pharmaceuticals has announced an increase in the complete remission (CR) rate in patients with frontline or treatment-naïve high-risk myelodysplastic syndrome (HR-MDS), based on updated efficacy data from its Phase I/II BEXMAB trial.  According to the investigator-assessed response using IWG 2006 criteria, as per protocol, the CR… Read More

#News

Business financing
#Financing #mRNA #Oncology #Strand Therapeutics

Strand Therapeutics raises $153 million for mRNA therapies

Strand Therapeutics has announced a $153 million Series B funding led by Kinnevik, with new investors including Regeneron Ventures, ICONIQ, and Amgen Ventures.  The funding will advance Strand’s pipeline, led by STX-001, a programmable mRNA therapy that expresses the cytokine interleukin-12 (IL-12) directly from the tumour microenvironment.   The company recently… Read More

#Business & Investment #News

#Clinical trials #Diabetes #Duchenne muscular dystrophy #HIV #Immunology / Virology & Vaccines #Obesity #Oncology

This week in drug discovery (4-8 August) 

News round-up for 4-8 August by DDW Senior Digital Content Editor Diana Turner. In the week that the US Department of Health and Human Services cancelled multiple programmes investigating mRNA vaccines, a number of other clinical trials have made the headlines. The top stories:… Read More

#News

Human brain
#Brain cancer #FDA #Jazz Pharmaceuticals #Oncology

FDA approves first treatment for rare type of glioma

The US Food and Drug Administration (FDA) has granted accelerated approval for Modeyso (dordaviprone) for the treatment of patients one year of age and older with diffuse midline glioma harbouring an H3 K27M mutation with progressive disease following prior therapy.  The FDA has stated that continued approval for this indication… Read More

#News #Regulatory

CAR-T therapy for leukaemia
#CAR-T #Cell therapy #Haematology #In vivo #Lipid based nanoparticle (LNP) #NanoCell Therapeutics #Oncology

First non-viral DNA-based in vivo CAR-T generation

A new study has demonstrated the first stable, functional chimeric antigen receptor T-cells (CAR-T) cell generation in vivo using targeted lipid nanoparticles for DNA delivery.  The research evaluated NanoCell Therapeutics’ targeted lipid nanoparticle delivery system, termed NCtx, which enables the… Read More

#Cancer Research #News #Trending News

Funding concept
#Clinical trial #Funding #LIfT BioSciences #Oncology #Solid tumours

LIfT BioSciences receives €12m to support solid tumour trials

LIfT BioSciences has received a grant of €12 million from Ireland’s Disruptive Technologies Innovation Fund (DTIF) to advance its Immuno-Modulatory Alpha Neutrophils (IMANs), designed to overcome treatment resistance in solid tumours, through first-in-human clinical trials expected to start in Q4 2026.  The €12 million grant, the largest grant awarded by… Read More

#Business & Investment #News

Monoclonal antibodies
#FDA #Haematology #Myeloma #Oncology #Orphan drugs #Sanofi

Sanofi’s antibody earns orphan status for multiple myeloma

The US Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, an IgG1-based Antibody-Dependent Cellular Cytotoxicity-enhanced (ADCC) monoclonal antibody (mAb).  The mAb targets G-protein coupled receptor family C group 5 member D (GPRC5D) for the potential treatment of patients with relapsed or refractory multiple myeloma (R/R MM).  … Read More

#Cancer Research #News #Regulatory